Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Nominee Tavenner Gains Confirmation Momentum With Bipartisan Support At Senate Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

Senate Finance Committee greets Tavenner with multiple statements of support in her bid to become the first Senate-confirmed CMS administrator since 2006. She emphasizes “need to operate CMS as a business and act like business partners” with stakeholders.

You may also be interested in...



CMS Administrator-Nominee Tavenner Would Bring Leadership Continuity As ACA Implementation Continues

With the selection of Centers for Medicare and Medicaid Services Principal Deputy Administrator Marilyn Tavenner as Don Berwick’s successor, the Obama administration appears to be seeking leadership continuity with a candidate that has a good chance of gaining Senate confirmation.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Deal Watch: Sanofi, Boehringer Swap Side Businesses

Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS075648

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel